The role of preoperative axillary ultrasound and fine-needle aspiration cytology in identifying patients with extensive axillary lymph node involvement by Maráz, Róbert et al.
Available online at www.sciencedirect.com* Corresponding au
Teaching Hospital, N
E-mail addresses:
http://dx.doi.org/10.10
0748-7983/ 2017 E
ScienceDirect
EJSO 43 (2017) 2021e2028 www.ejso.comThe role of preoperative axillary ultrasound and fine-needle
aspiration cytology in identifying patients with extensive
axillary lymph node involvement
Robert Maraz a, Tamas Zombori b, Eva Ambrozay c,
Gabor Cserni b,d,*
aDepartment of Surgery, Bacs-Kiskun County Teaching Hospital, Nyiri ut 38, H6000 Kecskemet, Hungary
bDepartment of Pathology, University of Szeged, Allomas u 1, H6720 Szeged, Hungary
cDepartment of Breast Diagnostics, Mamma Zrt at Kecskemet, Nyiri ut 38, H6000 Kecskemet, Hungary
dDepartment of Pathology, Bacs-Kiskun County Teaching Hospital, Nyiri ut 38, H6000 Kecskemet, HungaryAccepted 4 August 2017
Available online 30 August 2017AbstractIntroduction: In the recent past, both clinically node-positive and node-negative but sentinel node-positive patients underwent axillary
lymph node dissection (ALND), although the two groups seem to have substantially different degree of nodal involvement.
Methods: Data on consecutive primary breast cancer patients with documented axillary ultrasound (AXUS) results who underwent ALND
between January 2003 and December 2015 either because of AXUS-guided fine needle aspiration (A-FNAC) results or because of a positive
sentinel lymph node were retrospectively analysed.
Results: After exclusions, 316 patients staged by SNB and ALND with negative AXUS or A-FNAC (group A) were compared with 159
patients having positive A-FNAC results (group B). Tumour size and the proportion of mastectomies were greater, histological grade higher
and lymphovascular invasion more frequent in Group B, where palpable lymph nodes were also more common. The proportion of cases
with extensive nodal involvement (pN2 and pN3 cases) was about 3 times as much in Group B (63%) than in Group A (18%). Removal of
the 50 patients with palpable lymph nodes from the analysis did not greatly influence these proportions: 60% and 19% extensive nodal
involvements were noted, respectively. In this series, patients with suspicious AXUS and negative A-FNAC had more often extensive nodal
involvement (25%) than AXUS negative patients (17%).
Conclusions: Patients in whom axillary metastases are detected by ultrasound-guided biopsy have significantly more involved nodes than
SLNB-positive patients, and therefore are likely to benefit from axillary treatment.
 2017 Elsevier Ltd, BASO ~ The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
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Axillary lymph node involvement is one of the most
important prognostic factors of breast cancer. Patients
without axillary node involvement have a significantly bet-
ter prognosis than patients with pN1-3 disease [1,2]. Both
the total number of nodes retrieved during axillary lymph
node dissection (ALND) (positive and negative ones) andthor. Department of Pathology, Bacs-Kiskun County
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lsevier Ltd, BASO ~ The Association for Cancer Surgery,the number of metastatic nodes have prognostic importance
[3,4]. Before the introduction of sentinel lymph node
biopsy (SLNB), elective ALND was performed in all
patients. By now, SLNB has replaced ALND in the staging
of the axilla in clinically node negative breast cancer
patients. In patients with a positive sentinel lymph node
(SLN), completion ALND had universally been performed
until recently. The American College of Surgeons
Oncology Group (ACOSOG) Z0011 trial reported equiva-
lent outcomes for SLNB alone compared to completion
ALND for women with 1e2 positive sentinel lymph nodes
undergoing breast-conserving surgery, whole-breastand the European Society of Surgical Oncology. All rights reserved.
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Z0011 trial, a clinically negative axilla was defined by
physical examination only, and it is recognized that axillary
palpation can have a relatively high (up to 45%) false-
negative rate [7]. Some studies suggest that axillary ultra-
sound (AXUS) and needle biopsy of abnormal-appearing
nodes can appropriately allocate node-positive women to
an up-front ALND, avoiding a 2-step axillary procedure
[8,9]. AXUS guided fine-needle aspiration cytology (A-
FNAC) of suspicious lymph nodes is recognized as an
optimal preoperative procedure for identifying patients
with an indication for ALND [10,11]. Clinical nodal stag-
ing nowadays often includes palpation, AXUS and A-
FNAC [12], as neither palpation, nor AXUS alone are
considered sufficient to indicate ALND. The present study
aimed to reinforce that A-FNAC is a reliable method to a
priori select patients with extensive metastatic nodal
involvement (defined as having more than 3 metastatic
lymph nodes) and distinguish them from those with no or
lower nodal load.
Patients and methods
From a series of 733 consecutive primary invasive breast
cancer patients with ALND, those who underwent either
A-FNAC and/or SLNB followed by ALND between
January 2003 and December 2015 at the Bacs-Kiskun
County Teaching Hospital were retrospectively analysed.
Patients with positive A-FNAC findings were compared
to those without preoperative microscopic proof of axillary
involvement. In a subset analysis, AXUS-negative cases
were also compared to patients with positive AXUS find-
ings but negative A-FNAC results. In the analysis, no
attempt was made to exclude patients with palpable axillary
lymph nodes due to the reportedly high false-positive rate
of this finding even when the axilla seems highly suspicious
on physical examination [7,13]. However, subset analyses
were performed to see whether or not the main conclusion
of the study holds true after the exclusion of patients with a
clinically positive axillary status based on palpation alone.
Patients who received neoadjuvant therapies, had distant
metastatic disease, recurrent rather than primary disease
and those who did not undergo an ALND were excluded.
The preoperative diagnosis of breast cancer was estab-
lished by mammography, ultrasonography and FNAC or
core needle biopsy (CNB) in all patients. Prior to surgery,
AXUS was performed routinely as part of the preoperative
assessment.
When AXUS was negative, the axillary staging proced-
ure was SLNB, and in case of a positive SLN identified
either intraoperatively (by means of imprint cytology) or
subsequently during the examination of permanent sec-
tions, completion ALND was generally done. In patients
with suspicious lymph nodes on AXUS [11,14], A-FNAC
was performed. When this yielded a negative result, the pa-
tient underwent SLNB. In patients with positive A-FNAC,we performed ALND along with the removal of the tumour
by either breast conserving surgery or mastectomy. ALND
consisted of the removal of level I and II axillary lymph no-
des [15].
Suspicious lymph nodes were defined as nodes that were
rounded, had an asymmetrical cortex, thicker than 3 mm or
lost the hyperechoic hilum. Suspicious nodes were aspi-
rated with a 23-gauge needle. Aspirates were either
smeared on a slide and fixed in 95% ethanol, or rinsed,
fixed in a 50% ethanole 2% polyethylene glycol solution,
and centrifuged, creating a monolayer preparation. Both
smears and monolayer slides were Papanicolaou stained.
Our technique of SLNB involved intraparenchymal
administration (intra- and/or peritumoral injection in 3e4
depots) of 60e90 MBq 99mTc-labelled colloids the day
before surgery: either 200e600 nm particle size Sentiscint
(Medi-Radiopharma Kft., Erd, Hungary) or 40e80 nm par-
ticle size colloids Nanoalbumon (Medi-Radiopharma Kft.,
Erd, Hungary) or Nanocoll (Gipharma, Saluggia, Italy).
From January 2006, we introduced superficial, periareolar
injection of the radiocolloid according to the localization
of the quadrant harboring the tumour as preferred method.
However, in case of non-palpable tumours, the radioactive
tracer was injected intraparenchymally, into and around
the tumour, with ultrasound (US) guidance to permit Radio-
guided Occult Lesion Localization (ROLL). Lymphoscin-
tigraphy was generally performed 2 h after the
administration of the radioactive tracer and was often
repeated the next day, shortly before surgery, to check
whether the highlighted lymph nodes are still there and
no further lymph nodes have appeared. Two ml Patent
Blue dye was injected intraparenchymally or periareolarly
above the tumour after the induction of general anesthesia,
10e15 min before the incision [16].
Staging and the discrimination of metastases, microme-
tastases and isolated tumour cells (ITC) was done accord-
ing to the Tumour Node Metastases (TNM) classification
of malignant tumours in effect during the study period [17].
Patient and tumour characteristics including age, type of
operation, tumour histology, tumour size, presence of
vascular invasion, histological grade, oestrogen receptor
(ER) and progesterone receptor (PR) status, human
epidermal growth factor receptor 2 (HER2)/neu status
based on overexpression or amplification were collected
along with the outcome measures of the study: axillary
nodal status, extra-capsular invasion and the type of axil-
lary metastasis. In the case of multifocal tumours, we
took into consideration the size of the largest invasive
tumour and the highest grade (if different).
Statistical models for the comparisons included ANOVA
on ranks as one-tailed univariate model (Sigmaplot 11.0,
Systat Software Inc. San Jose, CA, USA), and logistic
regression with backward selection as multivariate model
(Stata 9, StataCorp. LLC, College Station, TX, USA). For
the subset comparisons 2  2 contingency tables were
used and the chi-square test was used with Yates correction
2023R. Maraz et al. / EJSO 43 (2017) 2021e2028for continuity (Vassarstats, [18]) The significance level was
set at p < 0.05.
Results
Out of the 733 breast cancer patients with ALND per-
formed, 464 patients underwent SLNB prior to ALND. In
contrast, 269 had no SLNB before ALND (Fig. 1).
In the first group of patients we have found no records
on AXUS being performed in 139 cases because in the
early period examined, this was not routinely recorded.
Although these cases were likely to represent AXUS-
negative findings, they were excluded because of missing
data on AXUS. Nine further cases had to be excluded
because ALND had not been performed on the basis of
microscopically proven metastases in the SLN: the oper-
ating surgeon decided to perform ALND on the basis of in-
traoperative palpation or the presence of ITCs; imprint
cytology was suspicious but not positive in one of these
cases and false positive in another. Finally there remained
316 patients staged by SNB and ALND with data on
AXUS and A-FNAC if performed, (group A).
In the second group of patients, data on AXUS were
missing in 73 cases, and in further 37 cases there was no
AXUS performed: so finally 159 patients remained for
further analysis (group B) (Fig. 1, Table 1.)
The average tumour size of patients in group A was
significantly smaller than that of patients in group B. The
proportion of breast conserving surgery was significantlyFig. 1. Case selechigher for group A patients, justifiable by the larger average
tumour size in group B. Invasive ductal carcinoma (no spe-
cial type carcinoma) was the most common tumour type in
both groups of patients. Tumours were less differentiated in
group B than in group A (p < 0.001). Vascular invasion was
significantly more frequent in patients in group B
(Table 1.).
The main aim of our study was to compare the nodal
burden in patients with positive A-FNAC and positive
SLNB. We found that patients with positive A-FNAC
have significantly higher nodal burden (about 3 times as
much extensive nodal involvement) compared to SLNB
positive patients (p < 0.001). In group A, pN2 and pN3
cases composed 18% of patients, while in group B we
found three times as many of these categories (63%)
(Fig. 2).
Data on axillary staging by palpation were available in
all but 15 patients, these were excluded from the subset
analysis on physical examination. Altogether 50 patients
in the analysis had palpable lymph nodes, 4 (1.3%) in group
A and 46 (30.1%) in group B (p < 0.0001). Of the patients
who were clinically node negative on palpation, 59/304
(19.4%) had pN2 or pN3 nodal involvement in Group A,
whereas this rate was 64/109 (60.4%) in group B
(p < 0.0001). Eighty per cent of the pN2 and pN3 breast
cancers had no palpable lymph nodes.
Group A patients were divided into two subgroups
based on the result of the AXUS. In the first subgroup
(A1) there were no suspicious axillary nodes identified,tion details.
Table 1
Patient demographics and clinico-pathological characteristics in patholog-
ically node-positive Groups A (clinically node-negative staged by SLNB)
and B (clinically node-positive staged by ALND).
Group A Group B p value
Patients number 316 159
Average age 59 65 <0.001
Age <0.001
40 19 4
41e50 64 16
51e70 177 79
71 56 60
Type of operations <0.001
BCS 265 85
Mastectomy 51 74
Histological type 0.895
IDC 233 119
ILC 48 22
Others 35 18
Tumour size <0.001
pT1a-1b 24 5
pT1c 166 48
pT2 120 95
pT3 4 11
pT4 2 0
Vascular invasion 0.037
Absent 185 77
Present 131 82
Histological grade <0.001
1 65 17
2 133 48
3 118 94
Receptor statusa/b <0.001
ERþ 277 118 <0.001
ER 39 41
PRþ 245 106 0.011
PR 68 51
HER2þ 27 22 0.050
HER2 289 136
Outcome measures
Axillary nodal status <0.001
pN1 258 59
pN2 44 48
pN3 14 52
ECc 0.008
ECþ 156 99
EC- 159 60
MIC 69 2 <0.001
MAC 247 157 <0.001
Total number of nodes
excised (mean)
13.7 15.1 0.015
Significant values are highlighted in bold.
ALND: axillary lymph node dissection, BCS: breast conserving surgery,
EC: extracapsular spread, ER: oestrogen receptor, HER2: human
epidermal growth factor receptor 2, IDC: invasive ductal carcinoma (no
special type breast carcinoma), ILC: invasive lobular carcinoma, PR: pro-
gesterone receptor, MAC: macrometastasis, MIC: micrometastasis, SLNB:
sentinel lymph node biopsy.
a PR status was unknown in 3 cases from Group A and 2 cases from
Group B and these cases were not considered in the statistics.
b HER-2 status was unknown in 1 case from Group B and this case was
not considered in the statistics.
c Extracapsular spread was not assessable in 1 case from Group A, and
this case was therefore omitted from the statistics.
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subgroup (A2), FNAC was necessary. In the two sub-
groups, we analysed the axillary nodal status, extra-
capsular invasion, the type of axillary metastasis and the
average size of the maximal diameter of the SLN metas-
tasis. In a few cases, a lymph node metastasis was found
in a non-radioactive and non-blue lymph node removed
during SLNB, i.e. a non-SLN (NSLN) by restrictive defini-
tion; from a pragmatic approach, these were recorded
within the SLN metastasis group according to a more al-
lowing definition [19].
Patients in subgroup A2 (where A-FNAC was per-
formed) had significantly higher nodal burden, and the
rate of pN1 patients was significantly lower (75%)
compared to patients in subgroup A1 without FNAC
(83%) (Table 2) (Fig. 3). The other measures of nodal
involvement (i.e. rate of micrometastasis versus macrome-
tastasis, mean largest size of the SLN metastasis, rate of ex-
tracapsular extension) showed no significant differences
between the two subgroups.Discussion
The presence of axillary metastasis is one of the most
important prognostic factors in breast cancer [1,2,20], how-
ever it is important to remember that more than 60% of all
primary operable breast cancers do not have axillary lymph
node metastasis [21]. The diagnostic role of preoperative
AXUS and FNAC has increased significantly [22], as phys-
ical examination has been recognized to have a relatively
high false-negative and false-positive rate [7,12]. Patients
with no suspicious nodes on ultrasound imaging and those
with a negative ultrasound-guided biopsy might even be
spared the SLNB procedure. Several randomized clinical
trials (SOUND, INSEMA, NCT 01821768 and BOGG
2013-08) were initiated to clarify this scenario by random-
izing early breast cancer patients between SLNB and no
SLNB after negative AXUS/FNAC [23e26]. These studies
demonstrated the need to clarify the role of A-FNAC in de-
tecting extensive nodal involvement, too.
Our study shows that patients with a positive A-FNAC
have a substantially higher nodal tumour burden than those
with a positive SLNB. Patients in the A-FNAC group were
also statistically more likely to undergo a mastectomy, to
have a higher tumour grade and extranodal extension.
This group was found to have higher numbers of ER-
negative and HER2-positive tumours. These results are
similar to those found in other studies [27,28]. The meta-
analysis by van Wely et al. [29] shows that 56% of the pa-
tients with positive A-FNAC have three or more positive
ALNs, and the other big study by G.M. Kramer et al.
[30] shows almost identical numbers, with a positive pre-
dictive value (PPV) of 58%. These patients could probably
benefit from additional axillary treatment.
Fig. 2. Nodal involvement according to pTNM categories in Groups A and B.
Table 2
Comparison of the clinically node-negative patients undergoing SLNB and ALND according to the AXUS findings.
A1: No suspicion on AXUS,
therefore no FNAC
A2: Suspicion on AXUS,
therefore FNAC performed, but
negative for metastasis
p value
Patients number 272 44
pN1 225 33 0.011
pN2 39 5
pN3 8 6
ECa
ECþ 132 24 0.45
EC 139 20
MIC 61 8 0.19
MAC 211 36
Mean maximum size of SLN
metastasis (mm)
6.2 7.83 0.47
Significant values are highlighted in bold.
ALND: axillary lymph node dissection, AXUS: axillary ultrasound, EC: extra capsular spread, FNAC: fine needle aspiration cytology, MAC: macrometa-
stasis, MIC: micrometastasis, mm: millimeter, SLN: sentinel lymph node, SLNB: sentinel lymph node biopsy.
a Extracapsular spread was not assessable in 1 case from Group A1, and was therefore omitted from the statistics.
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Fig. 3. Nodal involvement according to pTNM categories in Subgroups A1 and A2.
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burden between those who had suspicious axillary ultra-
sound findings but a negative A-FNAC and those who
had an initial negative AXUS [29]. In contrast, we have
found a significant difference between these groups in
terms of nodal burden (p ¼ 0.017), (Table 2). This may
be due to the small case numbers, but can also be related
to false-negative A-FNAC results. AXUS alone seems to
be of relatively high (83%) specificity and 71% sensitivity
in identifying the group of patients with 3 lymph nodes
involved [31,32], but A-FNAC may still miss some of
these cases. Indeed, AXUS-guided core biopsies were
found to have a higher positive predictive value and sensi-
tivity than A-FNAC in identifying axillary lymph node
metastases preoperatively [33]. At present, both patients
with a negative AXUS findings, and those with suspicious
AXUS findings but negative A-FNAC should be consid-
ered clinically node negative, and most will have low
nodal burden (pN1 disease) in the axilla: 83% and 75%,
respectively on the basis of our data; although these ratesare statistically different, this difference may be of limited
clinical importance.
Our results, in keeping with previous studies demon-
strate that clinically node positive breast cancer patients
are different from clinically node negative and pathologi-
cally node positive patients.
Conclusions
Although clinically node-negative breast cancer patients
with SLNB proven lymph node involvement of the axilla
and those (clinically node-positive) with A-FNAC proven
nodal involvement are both node-positive, they differ signif-
icantly in terms of nodal tumour burden. Patients in whom
axillary metastases are detected by ultrasound-guided bi-
opsy have significantly more involved nodes than SLNB-
positive patients, and therefore are expected to have a worse
prognosis; it is believed that they are more likely to benefit
from further axillary treatment than patients with no preop-
erative biopsy proven evidence of nodal involvement.
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